HRP20180815T8 - Prolijekovi fosforamidne kiseline 5-[5-fenil-4-(piridin-2-ilmetilamino)hinazolin-2-il]piridin-3-sulfonamida - Google Patents

Prolijekovi fosforamidne kiseline 5-[5-fenil-4-(piridin-2-ilmetilamino)hinazolin-2-il]piridin-3-sulfonamida

Info

Publication number
HRP20180815T8
HRP20180815T8 HRP20180815TT HRP20180815T HRP20180815T8 HR P20180815 T8 HRP20180815 T8 HR P20180815T8 HR P20180815T T HRP20180815T T HR P20180815TT HR P20180815 T HRP20180815 T HR P20180815T HR P20180815 T8 HRP20180815 T8 HR P20180815T8
Authority
HR
Croatia
Prior art keywords
ylmethylamino
quinazolin
sulfonamide
pyridin
pyridine
Prior art date
Application number
HRP20180815TT
Other languages
English (en)
Croatian (hr)
Inventor
Jayakumar S. Warrier
Navnath Dnyanoba Yadav
Original Assignee
Bristol-Myers Squibb Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol-Myers Squibb Company filed Critical Bristol-Myers Squibb Company
Publication of HRP20180815T1 publication Critical patent/HRP20180815T1/hr
Publication of HRP20180815T8 publication Critical patent/HRP20180815T8/hr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6509Six-membered rings
    • C07F9/6512Six-membered rings having the nitrogen atoms in positions 1 and 3
    • C07F9/65128Six-membered rings having the nitrogen atoms in positions 1 and 3 condensed with carbocyclic rings or carbocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/675Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10Laxatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/06Antiarrhythmics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Nutrition Science (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
HRP20180815TT 2012-06-11 2013-06-10 Prolijekovi fosforamidne kiseline 5-[5-fenil-4-(piridin-2-ilmetilamino)hinazolin-2-il]piridin-3-sulfonamida HRP20180815T8 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261657913P 2012-06-11 2012-06-11
EP13730444.0A EP2858987B1 (en) 2012-06-11 2013-06-10 Phosphoramidic acid prodrugs of 5-[5-phenyl-4-(pyridin-2-ylmethylamino)quinazolin-2-yl]pyridine-3-sulfonamide
PCT/US2013/044882 WO2013188254A1 (en) 2012-06-11 2013-06-10 Phosphoramidic acid prodrugs of 5 - [5 - phenyl- 4 - (pyridin- 2 - ylmethylamino) quinazolin- 2 - yl] pyridine- 3 - sulfonamide

Publications (2)

Publication Number Publication Date
HRP20180815T1 HRP20180815T1 (hr) 2018-06-29
HRP20180815T8 true HRP20180815T8 (hr) 2019-02-08

Family

ID=48670111

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20180815TT HRP20180815T8 (hr) 2012-06-11 2013-06-10 Prolijekovi fosforamidne kiseline 5-[5-fenil-4-(piridin-2-ilmetilamino)hinazolin-2-il]piridin-3-sulfonamida

Country Status (34)

Country Link
US (1) US9238666B2 (enExample)
EP (1) EP2858987B1 (enExample)
JP (1) JP6234450B2 (enExample)
KR (1) KR102092984B1 (enExample)
CN (1) CN104350048B (enExample)
AR (1) AR091402A1 (enExample)
AU (1) AU2013274619B2 (enExample)
BR (1) BR112014030629B1 (enExample)
CA (1) CA2876359C (enExample)
CL (1) CL2014003361A1 (enExample)
CO (1) CO7160032A2 (enExample)
CY (1) CY1120432T1 (enExample)
DK (1) DK2858987T3 (enExample)
EA (1) EA024692B1 (enExample)
ES (1) ES2675314T3 (enExample)
HR (1) HRP20180815T8 (enExample)
HU (1) HUE039210T2 (enExample)
IL (1) IL236074A (enExample)
LT (1) LT2858987T (enExample)
MX (1) MX356699B (enExample)
MY (1) MY169219A (enExample)
NZ (1) NZ703632A (enExample)
PE (1) PE20150228A1 (enExample)
PH (1) PH12014502747B1 (enExample)
PL (1) PL2858987T3 (enExample)
PT (1) PT2858987T (enExample)
RS (1) RS57376B1 (enExample)
SG (1) SG11201408076WA (enExample)
SI (1) SI2858987T1 (enExample)
SM (1) SMT201800369T1 (enExample)
TN (1) TN2014000499A1 (enExample)
TW (1) TWI571470B (enExample)
WO (1) WO2013188254A1 (enExample)
ZA (1) ZA201500161B (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105008366B (zh) * 2013-03-11 2017-11-14 百时美施贵宝公司 作为钾离子通道抑制剂的吡咯并哒嗪类化合物
US9050345B2 (en) * 2013-03-11 2015-06-09 Bristol-Myers Squibb Company Pyrrolotriazines as potassium ion channel inhibitors
JP6395798B2 (ja) * 2013-03-11 2018-09-26 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company カリウムイオンチャネル阻害剤としてのピロロトリアジン
ES2969792T3 (es) * 2015-11-19 2024-05-22 Biohaven Therapeutics Ltd Profármacos de amina de compuestos farmacéuticos

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5612359A (en) 1994-08-26 1997-03-18 Bristol-Myers Squibb Company Substituted biphenyl isoxazole sulfonamides
GB9514380D0 (en) * 1995-07-13 1995-09-13 Knoll Ag Therapeutic agents
TW536540B (en) 1997-01-30 2003-06-11 Bristol Myers Squibb Co Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe
KR20010083092A (ko) 1998-07-06 2001-08-31 스티븐 비. 데이비스 이중 안지오텐신 엔도텔린 수용체 길항제로서의 비페닐술폰아미드
ES2215474B1 (es) 2002-12-24 2005-12-16 J. URIACH & CIA S.A. Nuevos derivados de fosforamida.
AR049847A1 (es) 2004-07-29 2006-09-06 Merck & Co Inc Inhibidores de los canales de potasio
WO2006066879A2 (en) * 2004-12-21 2006-06-29 Devgen N.V. Compounds with kv4 ion channel activity
EP3575288B1 (en) 2009-09-03 2021-10-27 Bristol-Myers Squibb Company Quinazolines as potassium ion channel inhibitors
WO2011029054A1 (en) 2009-09-04 2011-03-10 The Regents Of The University Of Michigan Compositions and methods for treatment of leukemia
AR079814A1 (es) 2009-12-31 2012-02-22 Otsuka Pharma Co Ltd Compuestos heterociclicos, composiciones farmaceuticas que los contienen y sus usos
JP5848761B2 (ja) * 2010-06-24 2016-01-27 アルカーメス ファーマ アイルランド リミテッド Nh酸性化合物のプロドラッグ:エステル、カルボネート、カルバメートおよびホスホネートの誘導体
JP2016516691A (ja) * 2013-03-11 2016-06-09 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company カリウムイオンチャネル阻害剤としてのイソキノリン
US9242966B2 (en) * 2013-03-11 2016-01-26 Bristol-Myers Squibb Company Phthalazines as potassium ion channel inhibitors
US9050345B2 (en) * 2013-03-11 2015-06-09 Bristol-Myers Squibb Company Pyrrolotriazines as potassium ion channel inhibitors

Also Published As

Publication number Publication date
PT2858987T (pt) 2018-07-04
CA2876359C (en) 2020-01-21
KR102092984B1 (ko) 2020-03-24
US9238666B2 (en) 2016-01-19
SMT201800369T1 (it) 2018-09-13
AR091402A1 (es) 2015-02-04
PE20150228A1 (es) 2015-02-19
DK2858987T3 (en) 2018-07-30
PH12014502747A1 (en) 2015-02-02
HUE039210T2 (hu) 2018-12-28
HRP20180815T1 (hr) 2018-06-29
LT2858987T (lt) 2018-07-10
HK1203928A1 (en) 2015-11-06
MY169219A (en) 2019-03-19
SI2858987T1 (en) 2018-06-29
WO2013188254A1 (en) 2013-12-19
IL236074A (en) 2016-08-31
US20150175641A1 (en) 2015-06-25
BR112014030629A2 (pt) 2017-06-27
EP2858987A1 (en) 2015-04-15
PL2858987T3 (pl) 2018-08-31
JP2015521598A (ja) 2015-07-30
EA024692B1 (ru) 2016-10-31
TWI571470B (zh) 2017-02-21
PH12014502747B1 (en) 2015-02-02
MX2014014525A (es) 2015-02-24
CN104350048B (zh) 2016-12-07
CA2876359A1 (en) 2013-12-19
EP2858987B1 (en) 2018-04-25
AU2013274619B2 (en) 2017-09-28
CN104350048A (zh) 2015-02-11
AU2013274619A1 (en) 2015-01-29
BR112014030629B1 (pt) 2021-12-21
JP6234450B2 (ja) 2017-11-22
MX356699B (es) 2018-06-11
CY1120432T1 (el) 2019-07-10
KR20150023667A (ko) 2015-03-05
TW201402592A (zh) 2014-01-16
SG11201408076WA (en) 2015-01-29
EA201492256A1 (ru) 2016-05-31
NZ703632A (en) 2016-01-29
IL236074A0 (en) 2015-02-01
CO7160032A2 (es) 2015-01-15
ZA201500161B (en) 2017-04-26
CL2014003361A1 (es) 2015-05-29
ES2675314T3 (es) 2018-07-10
TN2014000499A1 (en) 2016-03-30
RS57376B1 (sr) 2018-08-31

Similar Documents

Publication Publication Date Title
IL270262A (en) Nucleic acids for treatment of allergies
CL2014003498A1 (es) Carboxamidas heterocíclicas fungicidas
DK3536310T3 (da) Sprøjte
DK3381444T3 (da) Sprøjte
EP2832391A4 (en) SYRINGE
EP2914731A4 (en) REVERSIBLE GENE EXPRESSION
EP2913076A4 (en) SYRINGE
EP2820952A4 (en) suspoemulsion
EP2883547A4 (en) MEDICINE
HRP20180815T8 (hr) Prolijekovi fosforamidne kiseline 5-[5-fenil-4-(piridin-2-ilmetilamino)hinazolin-2-il]piridin-3-sulfonamida
FI9859U1 (fi) Järjestely taakkojen käsittelemiseksi
UA25009S (uk) Сервант
UA25176S (uk) Сервант
FR2987422B1 (fr) Plateforme stabilisee
TH1401001018B (th) ชิ้นส่วนลดทอนปริมาณเหลือ
TH148762B (th) อนุพันธ์ของพิร์โรลิดีน-3-อิลแอซีติก แอซิด
UA25012S (uk) Сервант комбінований
UA25006S (uk) Сервант кутовий
EP2885023A4 (en) SYRINGE